266 related articles for article (PubMed ID: 23786997)
1. Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma.
Tomonaga N; Nakamura Y; Yamaguchi H; Ikeda T; Mizoguchi K; Motoshima K; Doi S; Nakatomi K; Iida T; Hayashi T; Nagayasu T; Tsukamoto K; Kohno S
Clin Lung Cancer; 2013 Sep; 14(5):521-6. PubMed ID: 23786997
[TBL] [Abstract][Full Text] [Related]
2. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
[TBL] [Abstract][Full Text] [Related]
3. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
[TBL] [Abstract][Full Text] [Related]
4. EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.
Lee JS; Kim HR; Lee CY; Shin M; Shim HS
Ann Surg Oncol; 2013 Sep; 20(9):3015-22. PubMed ID: 23525704
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.
Blons H; Côté JF; Le Corre D; Riquet M; Fabre-Guilevin E; Laurent-Puig P; Danel C
Am J Surg Pathol; 2006 Oct; 30(10):1309-15. PubMed ID: 17001163
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
[TBL] [Abstract][Full Text] [Related]
7. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
[TBL] [Abstract][Full Text] [Related]
8. Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.
Ikeda T; Nakamura Y; Yamaguchi H; Tomonaga N; Doi S; Nakatomi K; Iida T; Motoshima K; Mizoguchi K; Nagayasu T; Tsukamoto K; Kohno S
Clin Lung Cancer; 2012 Sep; 13(5):369-74. PubMed ID: 22410386
[TBL] [Abstract][Full Text] [Related]
9. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Malapelle U; Bellevicine C; De Luca C; Salatiello M; De Stefano A; Rocco D; de Rosa N; Vitiello F; Russo S; Pepe F; Iaccarino A; Micheli P; Illiano A; Carlomagno C; Piantedosi FV; Troncone G
Cancer Cytopathol; 2013 Oct; 121(10):552-60. PubMed ID: 23780873
[TBL] [Abstract][Full Text] [Related]
10. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer.
Hsieh RK; Lim KH; Kuo HT; Tzen CY; Huang MJ
Chest; 2005 Jul; 128(1):317-21. PubMed ID: 16002952
[TBL] [Abstract][Full Text] [Related]
11. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.
Sakuma Y; Matsukuma S; Yoshihara M; Nakamura Y; Noda K; Nakayama H; Kameda Y; Tsuchiya E; Miyagi Y
Am J Clin Pathol; 2007 Jul; 128(1):100-8. PubMed ID: 17580276
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung.
Yoshida Y; Shibata T; Kokubu A; Tsuta K; Matsuno Y; Kanai Y; Asamura H; Tsuchiya R; Hirohashi S
Lung Cancer; 2005 Oct; 50(1):1-8. PubMed ID: 15950315
[TBL] [Abstract][Full Text] [Related]
13. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma.
Haneda H; Sasaki H; Lindeman N; Kawano O; Endo K; Suzuki E; Shimizu S; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Jpn J Clin Oncol; 2006 Feb; 36(2):69-75. PubMed ID: 16449241
[TBL] [Abstract][Full Text] [Related]
14. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
[TBL] [Abstract][Full Text] [Related]
15. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.
Fujita Y; Suda K; Kimura H; Matsumoto K; Arao T; Nagai T; Saijo N; Yatabe Y; Mitsudomi T; Nishio K
J Thorac Oncol; 2012 Nov; 7(11):1640-4. PubMed ID: 22899358
[TBL] [Abstract][Full Text] [Related]
16. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
17. Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma.
Matsumoto S; Iwakawa R; Kohno T; Suzuki K; Matsuno Y; Yamamoto S; Noguchi M; Shimizu E; Yokota J
Int J Cancer; 2006 May; 118(10):2498-504. PubMed ID: 16353158
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
19. Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component.
Zhong WZ; Wu YL; Yang XN; Guo AL; Su J; Zhang XC; Luo DL; Wang Z; Chen HJ; Zhou Q; Xu CR; Qiao GB; Liao RQ; Yang JJ; Mok TS
Clin Lung Cancer; 2010 May; 11(3):160-8. PubMed ID: 20439191
[TBL] [Abstract][Full Text] [Related]
20. Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type.
Ninomiya H; Hiramatsu M; Inamura K; Nomura K; Okui M; Miyoshi T; Okumura S; Satoh Y; Nakagawa K; Nishio M; Horai T; Miyata S; Tsuchiya E; Fukayama M; Ishikawa Y
Lung Cancer; 2009 Feb; 63(2):235-40. PubMed ID: 18571764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
